BIOMAT Database Logo BIOMAT Database Logo

Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line. 1999

T Fukushima, and H Takemura, and T Yamashita, and T Ishisaka, and K Inai, and S Imamura, and Y Urasaki, and T Ueda
First Department of Internal Medicine, Fukui Medical University, Japan. tfukus@fmsrsa.fukui-med.ac.jp

We established a VP-16-resistant line of human leukemia cells, K562/VP-H2, derived from K562 cells. K562/VP-H2 cells were 44-fold more resistant to VP-16 than were K562 cells. K562/VP-H2 cells were also resistant to doxorubicin, daunorubicin and mitoxantrone, but showed little or no resistance to vincristine, aclarubicin, idarubicin, idarubicinol, cytosine arabinoside, cis-platinum or camptothecin. K562/VP-H2 cells did not over-express P-glycoprotein or multidrug resistance protein, and showed intracellular accumulation of VP-16 similar to that in K562 cells. While the expressions of topoisomerase II-alpha gene and topoisomerase II-beta gene, or catalytic activity in nuclear extract of K562/VP-H2 cells were similar to that of K562 cells, the VP-16 induced DNA cleavage was reduced in K562/VP-H2 cells compared to K562 cells, suggesting that the reduction of topoisomerase II-mediated DNA cleavage through qualitative alteration of topoisomerase II may be the main mechanism of acquired multidrug resistance for K562/VP-H2 cells. The K562/VP-H2 cell line is an interesting model for studying resistance to antileukemia drugs targeting topoisomerase II.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D002384 Catalysis The facilitation of a chemical reaction by material (catalyst) that is not consumed by the reaction. Catalyses
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D015971 Gene Expression Regulation, Enzymologic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in enzyme synthesis. Enzymologic Gene Expression Regulation,Regulation of Gene Expression, Enzymologic,Regulation, Gene Expression, Enzymologic
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug

Related Publications

T Fukushima, and H Takemura, and T Yamashita, and T Ishisaka, and K Inai, and S Imamura, and Y Urasaki, and T Ueda
Reduced topoisomerase II-mediated DNA cleavage in VP-16 resistant human leukemic cell line.
January 1991, Anticancer research,
T Fukushima, and H Takemura, and T Yamashita, and T Ishisaka, and K Inai, and S Imamura, and Y Urasaki, and T Ueda
Isolation and characterization of VP-16 resistant human leukemia cell line.
January 1990, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
T Fukushima, and H Takemura, and T Yamashita, and T Ishisaka, and K Inai, and S Imamura, and Y Urasaki, and T Ueda
Radiation resistance in a multidrug resistant human T-cell leukemia line.
October 1988, International journal of radiation oncology, biology, physics,
T Fukushima, and H Takemura, and T Yamashita, and T Ishisaka, and K Inai, and S Imamura, and Y Urasaki, and T Ueda
Characterization of resistance to VP-16 in human leukemic cell line.
December 1989, The Tohoku journal of experimental medicine,
T Fukushima, and H Takemura, and T Yamashita, and T Ishisaka, and K Inai, and S Imamura, and Y Urasaki, and T Ueda
FK506 reverses adriamycin resistance in a multidrug-resistant human leukemia cell line.
December 1992, The Kobe journal of medical sciences,
T Fukushima, and H Takemura, and T Yamashita, and T Ishisaka, and K Inai, and S Imamura, and Y Urasaki, and T Ueda
Reduced DNA topoisomerase II in VP-16 resistant mouse breast cancer cell line.
January 1990, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
T Fukushima, and H Takemura, and T Yamashita, and T Ishisaka, and K Inai, and S Imamura, and Y Urasaki, and T Ueda
Establishment of an etoposide (VP-16)-resistant subline of THP-1 human monocytic leukemia cell line.
March 1989, The Tohoku journal of experimental medicine,
T Fukushima, and H Takemura, and T Yamashita, and T Ishisaka, and K Inai, and S Imamura, and Y Urasaki, and T Ueda
Mechanism of multidrug resistance of human small cell lung cancer cell line H446/VP.
November 2010, Chinese medical journal,
T Fukushima, and H Takemura, and T Yamashita, and T Ishisaka, and K Inai, and S Imamura, and Y Urasaki, and T Ueda
Non-ionic detergent Tween 80 modulates VP-16 resistance in classical multidrug resistant K562 cells via enhancement of VP-16 influx.
February 2000, Cancer letters,
T Fukushima, and H Takemura, and T Yamashita, and T Ishisaka, and K Inai, and S Imamura, and Y Urasaki, and T Ueda
Relationship of VP-16 to the classical multidrug resistance phenotype.
May 1992, Cancer research,
Copied contents to your clipboard!